We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 89

“Perfect match” of claims and the authorized product required for patent listing under the NOC regulations

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • April 11 2014

This was an application for judicial review of a decision of the Minister of Health (“Minister”) which denied the listing of Eli Lilly Canada Inc.’s

Federal Court of Appeal weighs in on section 8 damage quantification

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • March 27 2014

On March 14, 2014, the Federal Court of Appeal released two decisions with respect to proceedings commenced pursuant to section 8 of thePatented

Federal Court dismisses application for a prohibition order in respect of PATADAY eye drop solution

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • March 18 2014

This case concerns a proposed generic version of the brand name drug PATADAY, an eye drop solution used to treat allergic and inflammatory eye

Supreme Court of Canada grants Apotex leave to appeal (again) in regard to the PLAVIX Patent

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • January 31 2014

On January 30, 2014, the Supreme Court of Canada (“SCC”) granted Apotex Inc., et al. (“Apotex”) leave to appeal the July 24, 2013 Federal Court of

Federal Court considers functional antibody claims valid and infringed

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • January 24 2014

The Federal Court has issued the first decision in Canada addressing the alleged infringement and validity of humanized antibody claims

Amended Patent Rules concerning Final Action procedures and re-examination proceedings

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • January 7 2014

Amended Patent Rules concerning Final Action procedures and re-examination proceedings were published in Part II of the Canada Gazette on December 18

Federal Court confirms that declaration of patent invalidity does not void earlier prohibition order

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • December 11 2013

This case dealt with an appeal by Apotex Inc. (Apotex) from a decision of Justice Gauthier in T-156-05 and T-787-05 which dismissed Apotex’s motion

Computer implemented inventions promisingly permitted by PAB

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • November 20 2013

In March 2013, the Canadian Intellectual Property Office (CIPO) released practice guidelines (Exam Memo PN 2013-02 and PN 2013-03) regarding

Federal court applies restrained approach to promise of the patent and holds that methods of medical treatment are not patentable

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • October 29 2013

This case concerns a proposed generic version of the birth control combination drug YAZ (drospirenoneethinyl estradiol). Bayer Inc. and Bayer

Pharma in brief - Canada: Federal Court refuses stand-alone application to amend patent disclosure

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • October 28 2013

In this case, the Federal Court dealt with a sui generis application by the Applicant, F. Hoffmann-La Roche AG, based on ss 53(2) of the Patent Act